<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046224</url>
  </required_header>
  <id_info>
    <org_study_id>ST-920-201</org_study_id>
    <nct_id>NCT04046224</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the
      cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability
      of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A
      at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in
      humans should, importantly, enable reduction and potentially clearance of Fabry disease
      substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single
      dose of ST-920 and followed for a period of 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">November 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 12 months after the ST-920 infusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Sequential dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ST-920 is administered as a single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ST-920</intervention_name>
    <description>Single dose of investigational product ST-920</description>
    <arm_group_label>Sequential dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male ≥ 18 years of age

          -  Documented diagnosis of classical Fabry disease as defined by plasma or leukocytes
             α-Gal A activity and one or more characteristics of classical Fabry disease:

             i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma

        Exclusion Criteria:

          -  Known to be unresponsive to ERT

          -  Neutralizing antibodies to AAV2/6

          -  Currently receiving migalastat (Galafold™)

          -  eGFR ≤ 60 ml/min/1.73m2

          -  New York Heart Association Class III or higher

          -  Active infection with hepatitis A, B or C, HIV or TB

          -  History of liver disease such as secondary steatosis, non-alcoholic steatohepatitis
             (NASH) and cirrhosis, cholangitis or biliary disease within 6 months of informed
             consent; except for Gilbert's syndrome

          -  Abnormal circulating AFP

          -  Recent or continued hypersensitivity response to ERT within previous 6 months

          -  Current or history of systemic (IV or oral) immunomodulatory agent or steroid use in
             the past 6 months (topical treatment allowed).

          -  Contraindication to use of corticosteroids for immunosuppression

          -  History of malignancy except for non-melanoma skin cancer

          -  History of alcohol or substance abuse

          -  Participation in prior investigational interventional drug or medical device study
             within previous 3 months

          -  Prior treatment with a gene therapy product

          -  Known hypersensitivity to components of ST-920 formulation

          -  Any other reason that, in the opinion of the Site Investigator or Medical Monitor,
             would render the subject unsuitable for participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>510-307-7266</phone>
    <email>clinicaltrials@sangamo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn J Laney</last_name>
      <phone>404-778-8518</phone>
      <email>dawn.laney@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Wilcox, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Diethelm-Okita</last_name>
      <phone>612-625-1594</phone>
      <email>dieth001@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Chester B Whitley, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health Neurogenetics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Rodriguez</last_name>
      <phone>929-455-5108</phone>
      <email>Sara.rodriguez@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Heather Lau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karli Hedstrom</last_name>
      <phone>212-659-1450</phone>
      <phone_ext>81450</phone_ext>
      <email>karli.hedstrom@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Jaya Ganesh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Bailey</last_name>
      <phone>513-636-4507</phone>
      <email>laurie.bailey@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hopkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Fikry</last_name>
      <phone>571-308-1900</phone>
      <phone_ext>7</phone_ext>
      <email>jfikry@ldrtc.org</email>
    </contact>
    <investigator>
      <last_name>Ozlem Goker-Alpan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sangamo</keyword>
  <keyword>Rare</keyword>
  <keyword>Lysosomal Storage Disease</keyword>
  <keyword>Gene Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

